Previous Article | Next Article ![]()
Molecular and Cellular Biology, June 2000, p. 4320-4327, Vol. 20, No. 12
Peptide Biology Laboratories, The Salk
Institute for Biological Studies, La Jolla, California 92037
Received 10 January 2000/Returned for modification 18 February
2000/Accepted 22 March 2000
The cyclic AMP (cAMP)-responsive factor CREB promotes cellular gene
expression, following its phosphorylation at Ser133, via recruitment of
the coactivator paralogs CREB-binding protein (CBP) and p300. CBP and
p300, in turn, appear to mediate target gene induction via their
association with RNA polymerase II complexes and via intrinsic histone
acetyltransferase activities that mobilize promoter-bound nucleosomes.
In addition to cAMP, a wide variety of stimuli, including hypoxia, UV
irradiation, and growth factor addition, induce Ser133 phosphorylation
with stoichiometry and kinetics comparable to those induced by cAMP.
Yet a number of these signals are incapable of promoting target gene
activation via CREB phosphorylation per se, suggesting the presence of
additional regulatory events either at the level of CREB-CBP complex
formation or in the subsequent recruitment of the transcriptional
apparatus. Here we characterize a Tyr134Phe CREB mutant that behaves as
a constitutive activator in vivo. Like protein kinase A
(PKA)-stimulated wild-type CREB, the Tyr134Phe polypeptide was found to
stimulate target gene expression via the Ser133-dependent recruitment
of CBP and p300. Biochemical studies reveal that mutation of Tyr134 to
Phe lowers the Km for PKA phosphorylation and
thereby induces high levels of constitutive Ser133 phosphorylation in
vivo. Consistent with its constitutive activity, Tyr134Phe CREB
strongly promoted differentiation of PC12 cells in concert with
suboptimal doses of nerve growth factor. Taken together, these results
demonstrate that Ser133 phosphorylation is sufficient for cellular gene
activation and that additional signal-dependent modifications of CBP or
p300 are not required for recruitment of the transcriptional apparatus to the promoter.
A number of growth factors have been
shown to induce cellular responses via the reversible phosphorylation
of specific transcription factors. Phosphorylation, in turn, has been
found to activate these factors by a number of mechanisms including
nuclear import, DNA binding, and coactivator recruitment
(23). Cyclic AMP (cAMP) stimulates cellular gene expression,
for example, via the protein kinase A (PKA)-mediated phosphorylation of
CREB at Ser133 (20), and this modification enhances the
transactivation potential of CREB by promoting the recruitment of the
coactivator paralogs CREB-binding protein (CBP) and p300 (4,
28). Biochemical reconstitution studies suggest that CBP and p300
mediate target gene activation, in turn, via their association with RNA
polymerase II complexes (14, 25, 31, 32). In vitro
transcription studies with purified basal transcription factors reveal
that Ser133 phosphorylation of CREB is sufficient to recruit CBP-RNA polymerase II complexes and to induce transcription from a
cAMP-responsive promoter (33).
The solution structure of the CREB-CBP complex, which was determined by
using relevant interaction domains referred to as KID and KIX,
respectively, reveals that the phosphorylated KID domain of CREB
undergoes a random coil-to-helix transition upon binding to the KIX
domain of CBP (38). This transition in KID stabilizes
complex formation by promoting hydrophobic interactions with residues
lining a shallow hydrophobic groove in KIX (38). Phospho-Ser133 also forms direct contacts with residues in KIX that
account for approximately half of the free energy of complex formation
(35, 38). The direct participation of Ser133 and flanking
amino acids in coactivator recruitment illustrates a dual role for
these residues in substrate recognition and recruitment of the
transcriptional apparatus.
In addition to cAMP, a variety of stimuli, including hypoxia
(6), UV irradiation (24), and growth factor
addition (11, 19, 37, 39), have been shown to promote Ser133
phosphorylation of CREB with stoichiometry and kinetics comparable to
those induced by cAMP. But many of these pathways appear to be
incapable of stimulating target gene expression via CREB
phosphorylation per se (9), suggesting the presence of
additional regulatory events either at the level of CREB-CBP complex
formation or in the subsequent recruitment of the transcriptional apparatus.
In artificial recruitment assays with a GAL4-CBP chimera, PKA was found
to potentiate CBP activity directly (15, 28). Calcium-dependent induction of cellular genes via phospho-Ser133 CREB
was also reported to require a nuclear calcium signal that modulates
CBP transcriptional activity (12, 22). Ras-dependent growth
factors were apparently incapable of stimulating phospho-Ser133 CREB
activity, for example, due to a block in the nuclear calcium signal
(12).
In contrast with the results of the above studies, recombinant
Ser133-phosphorylated CREB appears competent to induce transcription from a CRE-luciferase reporter plasmid following its microinjection into mouse embryo fibroblasts, supporting the notion that Ser133 phosphorylation is indeed sufficient for target gene induction (2). The apparent discrepancy between these studies prompted us to search for mutant CREB polypeptides that associate with CBP
constitutively in vivo. Here we report a gain-of-function CREB
polypeptide that interacts constitutively with CBP, due to a mutation
that promotes Ser133 phosphorylation under basal conditions. Our
results demonstrate that Ser133 phosphorylation is sufficient for
association with CBP and p300 and for recruitment of the
transcriptional apparatus to the promoter.
Yeast two-hybrid assays and mammalian transfections.
Yeast
assays were performed with wild-type or Tyr134Phe GAL4-KID cDNAs
inserted into pAS2.1 (Clontech). The Tyr134Phe substitution was
generated by PCR mutagenesis and verified by manual sequencing. A CBP
(amino acids [aa] 226 to 1830)-GAL4 activation domain protein was
expressed from the yeast parent vector pACT2. Yeast GC1954 cells were
cotransformed with pAS2.1 KID or pAS2.1 Tyr134Phe KID mutant, and
pACT2-CBP vectors were cotransformed by lithium chloride-mediated transformation. Fluorescence polarization and phosphorylation assays.
Synthetic wild-type and Tyr134Phe mutant KID peptides (aa 119 to 147)
were phosphorylated in vitro with recombinant PKA (generous gift of S. Taylor, University of California, San Diego), N-terminally fluoresceinated, and evaluated by fluorescence polarization assay as
previously described (35). Quantitative phosphorylation
assays of CREB peptides were performed using increasing concentrations of synthetic CREB peptide (generous gift of J. Rivier, Salk Institute). Levels of 32P incorporation were measured on P-81 paper
after extensive washing with 10% trichloroacetic acid. Phosphatase
assays on 32P-labeled PKA-phosphorylated CREB peptides were
performed with purified PP-1 catalytic subunit (generous gift of M. Bollen) under standard conditions.
Phosphotryptic mapping.
293T cells were transfected with
GAL4-KID (8) and GAL Y134F-KID expression vectors containing
the GAL4 DNA binding domain fused to aa 100 to 160 of CREB. After
24 h, transfected cells were incubated with phosphate-free
Dulbecco's modified Eagle medium containing 10% dialyzed serum and 1 mCi of [32P]orthophosphate/ml. After a 4-h incubation,
the cells were treated with vehicle or forskolin (10 µM) for 25 min,
washed with cold phosphate-buffered saline, and harvested in sodium
dodecyl sulfate (SDS) lysis buffer (0.5% SDS, 50 mM Tris [pH 8.0], 1 mM EDTA) containing a cocktail of phosphatase inhibitors (100 mM sodium fluoride, 1 mM sodium vanadate, 25 mM Differentiation of PC12 cells.
PC12 cells (106)
in 100-mm plates were cotransfected with CMV-green fluorescent protein
expression plasmid plus either wild-type or Tyr134Phe CREB expression
constructs by calcium phosphate precipitation. One day after
transfection, cells were stimulated with nerve growth factor (NGF) (10 or 100 ng/ml) in 1% horse serum plus Dulbecco's modified Eagle
medium. After an additional 3 days, transfected cells containing
neurites at least two cell diameters long were counted under the
fluorescent microscope. Results were repeated and confirmed in three
independent experiments.
In the course of yeast two-hybrid screening experiments to
identify mutations in the KID domain of CREB that alter its binding to
the KIX domain of CBP, we discovered a mutant Tyr134Phe KID peptide
with activity 10-fold higher than that of wild-type KID (Fig.
1A). Notably, Tyr134 is absolutely
conserved amongst CREB homologues, suggesting an important function for
this residue in transcriptional regulation (Fig. 1b).
0270-7306/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Characterization of a CREB Gain-of-Function Mutant
with Constitutive Transcriptional Activity In Vivo
![]()
ABSTRACT
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
![]()
INTRODUCTION
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
![]()
MATERIALS AND METHODS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
-Galactosidase assays were performed according to
standard protocols. The somatostatin chloramphenicol acetyltransferase (CAT) reporter construct (see Fig. 1D) contained 1.4 kb of promoter sequence. The mitogen-activated protein (MAP) kinase phosphatase reporter construct contained 1.6 kb of promoter sequence
(27) and was a generous gift of J. Dixon (University of
Michigan). The c-fos reporter gene (FC4-CAT) contained 400 bases of upstream promoter sequence (7).
Transient-transfection assays were performed with 293T cells as
previously reported (18), using a cotransfected cytomegalovirus (CMV)-
-galactosidase vector as the internal control.
-glycerophosphate, and 2 mM
sodium pyrophosphate). After boiling for 10 min, the lysate was cooled
to 4°C and precleared with 50 µl of protein A/G agarose. The
supernatants were diluted 1:5 with cold radioimmunoprecipitation assay buffer containing phosphatase and protease (1 mM
phenylmethylsulfonyl fluoride, 5 µM leupeptin, 10 µM pepstatin,
1 mM dithiothreitol) inhibitors and were immunoprecipitated for 2 to
4 h using anti-GAL4 DNA binding domain antibody (Santa Cruz) and
anti-CREB antibody (244). The immunoprecipitates were resolved by
SDS-polyacrylamide gel electrophoresis, and tryptic phosphopeptide maps
were developed as previously described (21).
![]()
RESULTS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References


View larger version (2121K):
[in a new window]
FIG. 1.
A gain-of-function Tyr134Phe CREB polypeptide stimulates
target gene expression in a Ser133-dependent manner. (A) Yeast
two-hybrid assay of pAS2.1 KID (WT) and pAS2.1 Tyr134Phe KID (Y/F)
constructs containing the GAL4 DNA binding domain fused to aa 100 to
160 of CREB. Yeast GC1954 cells were cotransformed with a pACT2-CBP
expression vector encoding CBP (aa 226 to 1830) fused to the GAL4
activation domain.
-Galactosidase activity derived from cells
containing the integrated GAL4 reporter is shown. (B) Amino acid
sequence alignment of KID domains in mammalian CREB family members
(CREB, ATF1, and CREM) and CREB homologues from Aplysia
(Aplys), Hydra, Drosophila (Droso), and
Caenorhabditis elegans (c. ele). The conserved Tyr134 is in
bold. The positions of
A and
B helices in KID are shown. (C)
(Left) CAT activity derived from CRE-CAT reporter cotransfected with
wild-type (WT) or Tyr134Phe mutant CREB (Y/F) expression plasmid in
293T cells. (Right) Activity of somatostatin (SMT), MAP kinase
phosphatase (MKP) and c-fos CAT reporter plasmids
following cotransfection with wild-type or Tyr134Phe CREB
expression plasmids into PC12 cells. (D) Luciferase activity derived
from 293T cells transfected with wild-type or Tyr134Phe mutant
GAL4-CREB expression plasmids containing the GAL4 DNA-binding domain
(aa 1 to 147) fused to the CREB transactivation domain (aa 1 to 283).
The effect of a PKA phosphoacceptor site (Ser/Ala133) mutation (S/A) on
activity of wild-type (W/T) and Tyr134Phe mutant (SY/AF) polypeptides
is also shown. CON, control; FSK, forskolin treated.
To test whether mutation of Tyr134 to Phe stimulates CREB activity in the context of the full-length protein, we performed transient-transfection assays in 293T cells. When cotransfected with a CRE reporter plasmid, Tyr134Phe CREB was eight times more active than wild-type CREB in unstimulated cells (Fig. 1C, left). Tyr134Phe CREB was also more active than wild-type CREB on several CRE-containing promoters in PC12 cells (Fig. 1C). Somatostatin, MAP kinase phosphatase-1, and c-fos reporter genes were all induced under basal conditions, although the level of induction by Tyr134Phe compared to wild-type CREB appeared to be highest on promoters containing simple CRE sites (somatostatin) versus multiple promoter-bound activators (MAP kinase phosphatase and c-fos) (Fig. 1C).
To rule out potential regulatory contributions from other mammalian CRE-binding proteins, we examined the activity of the Tyr134Phe CREB polypeptide in the context of a GAL4-CREB (1 to 283) construct lacking the basic region-leucine zipper domain. The Tyr134Phe mutant GAL4-CREB construct showed 10-fold higher activity than its wild-type counterpart under basal conditions (Fig. 1D). Addition of cAMP agonist further potentiated GAL4-Tyr134Phe CREB activity, although the induction of Tyr134Phe was lower than for wild-type GAL4-CREB (Fig. 1D). Illustrating the importance of the PKA phosphoacceptor site for the constitutive activity of Tyr134Phe CREB, mutation of Ser133 to alanine completely disrupted the activity of both wild-type and mutant (Tyr134Phe) constructs. These results demonstrate that transcriptional induction via Tyr134Phe CREB is Ser133 dependent (Fig. 1D).
To determine whether Tyr134Phe CREB stimulates transcription via CBP
recruitment, we performed mammalian two-hybrid studies using the
relevant interaction domains in CREB (KID) and CBP (KIX). In mammalian
two-hybrid assays, mutant Tyr134Phe GAL4-KID polypeptide was 10- to
20-fold more active than wild-type GAL4-KID under basal conditions
(Fig. 2A). Following cotransfection with
a KIX-VP16 expression vector, the activity of Tyr134Phe mutant GAL4-KID
but not wild-type GAL4-KID was enhanced fivefold, demonstrating that the Tyr134Phe mutation promotes a constitutive interaction between the
KID and KIX domains (Fig. 2A).
|
The adenovirus E1A oncoprotein has been shown to inhibit target gene
activation via CBP, in part by blocking its association with RNA
polymerase II complexes (3, 30, 33). As a further test of
Tyr134Phe activity, we performed transfection assays with wild-type E1A
or a CBP interaction-defective E1A construct (E1A
) (5).
Wild-type E1A reduced the basal activity of Tyr134Phe CREB about
10-fold, but E1A
had no effect, supporting the notion that Tyr134Phe
CREB stimulates target gene expression via a CBP-dependent pathway
(Fig. 2B).
To determine whether the constitutive activity of Tyr134Phe CREB is PKA dependent, we employed H89, a selective pharmacological inhibitor of PKA. 293T cells were transfected with a GAL4-Tyr134Phe CREB expression vector; after 24 h, the transfected cells were treated with H89 (10 µM) or vehicle for 6 h and were then assayed for luciferase activity derived from a cotransfected GAL4-luciferase reporter construct (Fig. 2C). Basal Tyr134Phe GAL4-CREB activity was blocked about 50% by H89 (Fig. 2C). In contrast, treatment with the MAP kinase-specific inhibitor PD98059 (20 µM) actually enhanced reporter activity somewhat, revealing that Tyr134Phe activity is dependent on a specific subset of cellular kinases (Fig. 2C).
Substrate recognition by PKA relies primarily on arginine residues
located at
2 and
3 relative to the serine phosphoacceptor site
(43). Supporting a role for PKA in target gene activation via Tyr134Phe CREB, mutagenesis of
3 (Arg130) or
2 (Arg131) arginines in GAL4-Tyr134Phe CREB to glutamine blocked reporter induction (Fig. 2D). In contrast, mutation of Arg135 or Lys136 to
glutamine in the context of Tyr134Phe CREB potentiated Tyr134 Phe CREB
activity about 40% (Fig. 2D). In this regard, basic residues C
terminal to the PKA phosphoacceptor site have been shown to function as
negative determinants of PKA phosphorylation (43), and
mutagenesis of these residues to glutamine would be predicted to
enhance substrate recognition by this kinase. Taken together, these
results indicate that Tyr134Phe CREB polypeptide induces cellular gene
expression via a CBP-dependent mechanism that requires basal PKA activity.
The importance of Ser133 and PKA activity for target gene induction via
Tyr134Phe CREB prompted us to examine Ser133 phosphorylation on the
mutant polypeptide in vivo. Although phospho-CREB levels are typically
evaluated by Western blot assay with phosphoSer133 CREB antiserum, the
importance of Tyr134 for recognition by this antibody precluded its use
in comparative phosphorylation experiments (not shown). Consequently,
we performed two-dimensional phosphotryptic mapping studies on
immunoprecipitates of wild-type and Tyr134Phe mutant GAL4-KID proteins
prepared from metabolically labeled 293T cells with a nondiscriminating
CREB antiserum (244). Western blot analysis of 293T cell lysates, using
either anti-GAL4 (Fig. 3A) or 244 antiserum (data not shown), revealed that wild-type and Tyr134Phe
mutant GAL4-KID polypeptides are comparably expressed in transfected
cells. Ser133 phosphorylation in unstimulated cells was four times
higher for the Tyr134Phe than for wild-type polypeptide (Fig. 3B,
compare spots A). In contrast, phosphorylation of an unrelated
phosphoacceptor site on KID was comparable in both wild-type GAL4-KID
polypeptides, demonstrating that Ser133 phosphorylation is specifically
enhanced in the mutant CREB polypeptide (Fig. 3B, compare spots B).
Consistent with their activation by cAMP agonist, both wild-type and
mutant proteins were inducibly phosphorylated in response to forskolin
treatment (10 µM, 25 min), although the level of Ser133
phosphorylation was two times higher in the mutant Tyr134Phe
polypeptide (Fig. 3B). These results demonstrate that the higher
activity of the Tyr134Phe CREB polypeptide is indeed correlated with
enhanced Ser133 phosphorylation in unstimulated cells.
|
We considered several scenarios to explain the altered activity of the
Tyr134Phe CREB protein; enhanced phosphorylation by PKA or other
cellular kinase, reduced dephosphorylation by the Ser/Thr phosphatase
PP-1, or higher affinity of the Ser133-phosphorylated Tyr134Phe
polypeptide for the KIX domain of CBP. To test these models, we
prepared synthetic peptides for wild-type and Tyr134Phe CREB, extending
from aa 119 to 147 and containing the minimal KIX interaction domain.
The affinity of mutant and wild-type CREB peptides for the KIX domain
was evaluated using a fluorescence polarization assay. Following
quantitative Ser133 phosphorylation by PKA and N-terminal fluorescein
addition, wild-type and Tyr134Phe peptides were incubated with
increasing concentrations of purified KIX peptide. The estimated
Kd values for complex formation with KIX were
516 nM for wild-type CREB and 730 nM for the Tyr134Phe mutant (Fig.
4A). The comparable binding affinity of
these peptides for KIX by fluorescence anisotropy assay is predicted by
the nuclear magnetic resonance structure of the KID-KIX complex, which
shows that the Tyr134 hydroxyl group is directed towards the solvent and is therefore unavailable for binding to residues in KIX or KID. By
providing similar hydrophobic contacts. Phe is therefore competent to
substitute for Tyr134.
|
The importance of the Ser-Thr phosphatase PP-1 in attenuating CREB activity in vivo (21) prompted us to test whether mutation of Tyr134 to Phe enhances CREB activity by reducing PP-1-mediated dephosphorylation at Ser133. Following incubation with purified catalytic subunit of PP-1, 32P-labeled wild-type and Tyr134Phe mutant phosphoSer133 CREB peptides were comparably dephosphorylated over the course of a 1-h incubation, indicating that PP-1 binds with similar affinity to wild-type and mutant CREB proteins. Thus, reduced dephosphorylation at Ser133 is unlikely to account for the constitutive activity of the Tyr134Phe CREB construct (Fig. 4B).
To test whether mutation of Tyr134 to Phe alters the Km of CREB for PKA, we performed phosphorylation experiments using synthetic wild-type or Tyr134Phe mutant peptides plus recombinant PKA. Remarkably, the Km for PKA, estimated by double-reciprocal plot, was fivefold lower for the mutant Tyr134Phe peptide (Km = 1.7 µM) than for the wild-type CREB peptide (Km = 8.9 µM) (Fig. 3C). This result is in agreement with the crystal structure of PKA, showing that residues at the P+1 position fit into a hydrophobic pocket within the catalytic cleft (26).
NGF has been reported to stimulate differentiation of PC12 cells, in
part via the MAP kinase-dependent phosphorylation of Elk-1 and via the
pp90RSK-mediated phosphorylation of CREB at Ser133
(40). The importance of CREB for induction of cellular genes
by NGF (1) prompted us to evaluate the ability of Tyr134Phe
CREB to promote differentiation of PC12 cells in conjunction with a
suboptimal NGF stimulus. Towards this end, we transfected PC12 cells
with expression vectors encoding constitutively active Tyr134Phe or
wild-type CREB polypeptides. The transfected cells were treated with
subthreshold doses of NGF (10 ng/ml) or vehicle (dimethyl sulfoxide).
After 3 days, PC12 cells transfected with empty vector alone showed no
change in cell morphology either in the control or with low-dose NGF treatment (Fig. 5). High-dose
(100-ng/ml)-NGF-treated PC12 cells showed abundant neurite extension as
expected (data not shown). Consistent with the requirement for
induction of Elk-1 activity, expression of Tyr134Phe CREB alone had no
effect on the morphology of untreated PC12 cells, despite high levels
of transcriptional activity by CRE reporter assay (Fig. 5 and data not
shown). Following treatment with low-dose NGF (10 ng/ml), however,
Tyr134Phe strongly induced neurite formation compared with
wild-type-CREB-transfected cells (Fig. 5). These results demonstrate
the ability of Tyr134Phe CREB to stimulate cellular gene expression in
concert with growth factor signals.
|
| |
DISCUSSION |
|---|
|
|
|---|
A number of signaling pathways have been found to promote Ser133 phosphorylation of CREB without concomitant induction of cellular genes. In this regard, recruitment of the transcriptional apparatus has been proposed to require the subsequent calcium- or cAMP-mediated induction of CBP transcriptional activity, perhaps via a phosphorylation-dependent mechanism (12).
In this report, we characterized a novel gain-of-function CREB mutant that promotes cellular gene expression in unstimulated cells, due to constitutive phosphorylation of the mutant polypeptide at Ser133. Biochemical reconstitution experiments indicate that mutation of Tyr134 to Phe lowers the Km of CREB for PKA, and studies with the pharmacological PKA inhibitor H89 implicate the involvement of basal PKA activity in this process. The crystal structure of the PKA catalytic subunit reveals that the +1 pocket preferentially recognizes bulky hydrophobic residues (26), and affinity selection assays with a randomized peptide library demonstrate that Leu and Phe are highly preferred by PKA at the +1 site (41). Preference for a Phe at +1 by PKA is also suggested by the yeast ADR1 transcriptional activator, which contains a high-affinity PKA recognition site (RRASF; Km = 0.23 µM) at Ser230 (13, 16). PKC family members also favor Phe at this position (34), suggesting the potential involvement of additional cellular kinases in phosphorylating the Tyr134Phe mutant CREB protein in vivo. However, as apparent evidence against a role for PKC in this process, down-regulation of PKC by prolonged (16-h) exposure to tetradecanocyl phorbol acetate had no effect on Tyr134Phe CREB activity in a transient-transfection assay (K. Du and M. Montminy, unpublished observations). Moreover, PKC family members often require basic residues downstream of the phosphoacceptor site (34), but mutagenesis of Arg135 and Lys136 actually potentiated Tyr134Phe CREB activity in 293T cells. These results support the notion that Tyr134Phe CREB is phosphorylated by PKA under basal conditions.
Tyr134 is absolutely conserved amongst CREB homologues, and our results suggest that this residue functions importantly as part of a rheostat mechanism that maintains low levels of Ser133 phosphorylation under basal conditions. In addition to kinase recognition, Tyr134 also functions importantly in complex formation with CBP. The solution structure of the KID-KIX complex reveals that Tyr134 forms hydrophobic contacts with residues in the shallow hydrophobic groove of KIX, as well as with hydrophobic residues in KID (Ile 128 and Leu138) (38). Indeed, mutagenesis of Tyr134 to Ala blocks association of phosphoSer133 CREB with KIX in vitro, demonstrating the dual role of this site in interfacing with the signaling machinery and in promoting recruitment of the transcriptional apparatus (35). Mutation of Tyr134 to Phe appears to be well tolerated by the complex; no change in binding affinity of the mutant Tyr134Phe KID peptide for KIX was observed relative to that of wild-type KID.
A number of studies have indicated that target gene activation in response to calcium and cAMP additionally requires signal-dependent phosphorylation of CBP (12). Although our data do not exclude the possibility that signal-dependent phosphorylation of CBP enhances target gene activation in response to calcium and cAMP, they indicate that Ser133 phosphorylation of CREB is sufficient for target gene activation without modification of other components in the transcriptional apparatus. These results are supported by in vitro transcription studies showing that CBP-polymerase II complexes are efficiently recruited to the promoter following Ser133 phosphorylation of CREB by PKA (33) and by cellular studies showing that phosphoSer133 CREB is transcriptionally active following microinjection into rat embryo fibroblasts (2). Moreover, CREB-myb and CREB-sterol response element binding protein fusion proteins containing sequences that permit constitutive binding to the KIX domain also show constitutive target gene activation via CBP (10, 36). Taken together, these observations argue that recruitment of CBP or p300 to the promoter is sufficient for induction of cellular genes.
The identification of a gain-of-function mutant in CREB that operates through the same mechanism as wild-type CREB should be of general interest in characterizing growth factor responses in various cell types. In this study, for example, we found that Tyr134Phe CREB cooperated with a suboptimal dose of NGF to promote differentiation of PC12 cells. CREB has also been shown to promote proliferation of certain endocrine cells, in part by stimulating the expression of cell cycle-dependent genes (17, 42, 44). Mutations in cytoplasmic proteins that regulate cAMP production have been shown, for example, to promote somatotroph proliferation and tumor progression in acromegalic patients (29). Based on the ability of a single amino acid substitution to dramatically induce CREB activity, it will be of interest to determine whether mutation of this site occurs naturally within a subset of endocrine tumors.
| |
ACKNOWLEDGMENTS |
|---|
We thank Jean Rivier for synthesis of CREB peptides, Ishwar Radhakrishnan and Peter Wright for advice on CREB-CBP structure, and Rusty Gage for help with microscopy. We also thank J. Dixon for the gift of map kinase phosphatase reporter plasmid.
This work was supported by NIH grant RO1-37828. H.A. is supported by JSPS postdoctoral fellowships for research abroad (FY1999).
Hiroshi Asahara and Ulupi Jhala contributed equally to this work.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: 10010 N. Torrey Pines Rd., Salk Institute, La Jolla, CA 92037. Phone: (858) 453-4100, ext. 1107. Fax: (858) 552-1546. E-mail: Montminy{at}Salk.edu.
| |
REFERENCES |
|---|
|
|
|---|
| 1. |
Ahn, S.,
M. Olive,
S. Aggarwal,
D. Krylov,
D. D. Ginty, and C. Vinson.
1998.
A dominant-negative inhibitor of CREB reveals that it is a general mediator of stimulus-dependent transcription of c-fos.
Mol. Cell. Biol.
18:967-977 |
| 2. |
Alberts, A.,
J. Arias,
M. Hagiwara,
M. Montminy, and J. Feramisco.
1994.
Recombinant cyclic AMP response element binding protein (CREB) phosphorylated on ser-133 is transcriptionally active upon its introduction into fibroblast nuclei.
J. Biol. Chem.
269:7623-7630 |
| 3. | Arany, Z., D. Newsome, E. Oldread, D. Livingston, and R. Eckner. 1995. A family of transcriptional adaptor proteins targeted by the E1A oncoprotein. Nature 374:8184. |
| 4. | Arias, J., A. Alberts, P. Brindle, F. Claret, T. Smeal, M. Karin, J. Feramisco, and M. Montminy. 1994. Activation of cAMP and mitogen responsive genes relies on a common nuclear factor. Nature 370:226-228[CrossRef][Medline]. |
| 5. |
Asahara, H.,
S. Dutta,
H.-Y. Kao,
R. M. Evans, and M. Montminy.
1999.
Pbx-Hox heterodimers recruit coactivator-corepressor complexes in an isoform-specific manner.
Mol. Cell. Biol.
19:8219-8225 |
| 6. |
Beitner-Johnson, D. M. D.
1998.
Hypoxia induces phosphorylation of the cyclic AMP response element-binding protein by a novel signaling mechanism.
J. Biol. Chem.
273:19834-19839 |
| 7. |
Bertherat, J.,
P. Chanson, and M. Montminy.
1995.
The cyclic adenosine 3',5'-adenosine-responsive factor CREB is constitutively activated in human somatotroph adenomas.
Mol. Endocrinol.
9:777-783 |
| 8. | Brindle, P., S. Linke, and M. Montminy. 1993. Protein-kinase-A dependent activator in transcription factor CREB reveals new role for CREM repressors. Nature 364:821-824[CrossRef][Medline]. |
| 9. |
Brindle, P.,
T. Nakajima, and M. Montminy.
1995.
Multiple PK-A regulated events are required for transcriptional induction by cAMP.
Proc. Natl. Acad. Sci. USA
92:10521-10525 |
| 10. |
Cardinaux, J.-R.,
J. C. Notis,
Q. Zhang,
N. Vo,
J. C. Craig,
D. M. Fass,
R. G. Brennan, and R. H. Goodman.
2000.
Recruitment of CREB binding protein is sufficient for CREB-mediated gene activation.
Mol. Cell. Biol.
20:1546-1552 |
| 11. |
Cesare, D. D.,
S. Jackquot,
A. Hanauer, and P. Sassone-Corsi.
1998.
Rsk-2 activity is necessary for epidermal growth factor-induced phosphorylation of CREB protein and transcription of c-fos gene.
Proc. Natl. Acad. Sci. USA
95:12202-12207 |
| 12. |
Chawla, S.,
G. E. Hardingham,
D. R. Quinn, and H. Bading.
1999.
CBP: a signal-regulated transcriptional coactivator controlled by nuclear calcium and CaM kinase IV.
Science
281:1505-1509 |
| 13. | Cherry, J. R., T. R. Johnson, C. Dollard, J. R. Shuster, and C. L. Denis. 1989. Cyclic AMP-dependent protein kinase phosphorylates and inactivates the yeast transcriptional activator ADR1. Cell 56:409-419[CrossRef][Medline]. |
| 14. |
Cho, H.,
G. Orphanides,
X. Sun,
X.-J. Yang,
V. Ogryzko,
E. Lees,
Y. Nakatani, and D. Reinberg.
1998.
A human RNA polymerase II complex containing factors that modify chromatin structure.
Mol. Cell. Biol.
18:5355-5363 |
| 15. | Chrivia, J. C., R. P. Kwok, N. Lamb, M. Hagiwara, M. R. Montminy, and R. H. Goodman. 1993. Phosphorylated CREB binds specifically to the nuclear protein CBP. Nature 365:855-859[CrossRef][Medline]. |
| 16. |
Denis, C. L.,
B. E. Kemp, and M. J. Zoller.
1991.
Substrate specificities for yeast and mammalian cAMP-dependent protein kinases are similar but not identical.
J. Biol. Chem.
266:17932-17935 |
| 17. | Desdouets, C., G. Matesic, C. A. Molina, N. S. Foulkes, P. Sassone-Corsi, C. Brechot, and J. Sobczak-Thepot. 1995. Cell cycle regulation of cyclin A gene expression by the cyclic AMP-responsive transcription factors CREB and CREM. Mol. Cell. Biol. 15:3301-3309[Abstract]. |
| 18. |
Du, K., and M. Montminy.
1998.
CREB is a regulatory target for the protein kinase Akt/PKB*.
J. Biol. Chem.
273:32377-32379 |
| 19. | Ginty, D., A. Bonni, and M. Greenberg. 1994. Nerve growth factor activates a Ras dependent protein kinase that stimulates c-fos transcription via phosphorylation of CREB. Cell 77:713-725[CrossRef][Medline]. |
| 20. | Gonzalez, G. A., and M. R. Montminy. 1989. Cyclic AMP stimulates somatostatin gene transcription by phosphorylation of CREB at serine 133. Cell 59:675-680[CrossRef][Medline]. |
| 21. | Hagiwara, M., A. Alberts, P. Brindle, J. Meinkoth, J. Feramisco, T. Deng, M. Karin, S. Shenolikar, and M. Montminy. 1992. Transcriptional attenuation following cAMP induction requires PP-1-mediated dephosphorylation of CREB. Cell 70:105-113[CrossRef][Medline]. |
| 22. | Hardingham, G. E., S. Chawla, F. H. Cruzalegui, and H. Bading. 1999. Control of recruitment and transcription-activating function of CBP determines gene regulation by NMDA receptors and L-type calcium channels. Neuron 22:789-798[CrossRef][Medline]. |
| 23. | Hunter, T., and M. Karin. 1992. The regulation of transcription by phosphorylation. Cell 70:375-387[CrossRef][Medline]. |
| 24. | Iordanov, M., K. Bender, T. Ade, W. Schmid, C. Sachsenmaier, K. Engel, M. Gaestel, H. J. Rahmsdorf, and P. Herrlich. 1997. CREB is activated by UVC through a p38/HOG-1-dependent protein kinase. EMBO J. 16:1009-1022[CrossRef][Medline]. |
| 25. |
Kee, B.,
J. Arias, and M. Montminy.
1996.
Adaptor mediated recruitment of RNA polymerase II to a signal dependent activator.
J. Biol. Chem.
271:2373-2375 |
| 26. |
Knighton, D. R.,
J. H. Zheng,
L. F. T. Eyck,
V. A. Ashford,
N. H. Xuong,
S. S. Taylor, and J. M. Sowadski.
1991.
Crystal structure of the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase.
Science
253:407-414 |
| 27. |
Kwak, S. P.,
D. J. Hakes,
K. J. Artell, and J. E. Dixon.
1994.
Isolation and characterization of a human dual specificity protein-tyrosine phosphatase gene.
J. Biol. Chem.
269:3596-3604 |
| 28. | Kwok, R., J. Lundblad, J. Chrivia, J. Richards, H. Bachinger, R. Brennan, S. Roberts, M. Green, and R. Goodman. 1994. Nuclear protein CBP is a coactivator for the transcription factor CREB. Nature 370:223-226[CrossRef][Medline]. |
| 29. |
Landis, C. A.,
S. B. Masters,
A. Spada,
A. M. Pace,
H. R. Bourne, and L. Vallar.
1989.
GTPase inhibiting mutations activate the chain of Gs and stimulate adenylyl cyclase in human pituitary tumours.
Nature
340:692-696[CrossRef][Medline].
|
| 30. | Lunblad, J., R. Kwok, M. Laurance, M. Harter, and R. Goodman. 1995. Adenoviral E1A associated protein p300 as a functional homologue of the transcriptional co-activator CBP. Nature 374:85-88[CrossRef][Medline]. |
| 31. |
McKenna, N.,
Z. Nawaz,
S. Tsai,
M. Tsai, and B. O'Malley.
1998.
Distinct steady-state nuclear receptor coregulator complexes exist in vivo.
Proc. Natl. Acad. Sci. USA
95:11697-11702 |
| 32. | Nakajima, T., C. Uchida, S. Anderson, C. Lee, J. Hurwitz, J. Parvin, and M. Montminy. 1997. RNA helicase A mediates association of CBP with RNA polymerase II. Cell 90:1107-1112[CrossRef][Medline]. |
| 33. |
Nakajima, T.,
C. Uchida,
S. Anderson,
J. Parvin, and M. Montminy.
1997.
Analysis of a cAMP-responsive activator reveals a two-component mechanism for transcriptional induction via signal-dependent factors.
Genes Dev.
11:738-747 |
| 34. | Nishikawa, K., A. Toker, F. J. Johannes, Z. Songyang, and L. C. Cantley. 1997. Determination of the specific substrate sequence motifs of protein kinase C isozymes. J. Biol. Chem. 252:952-960. |
| 35. | Parker, D., U. Jhala, I. Radhakrishnan, M. Yaffe, C. Reyes, A. Shulman, L. Cantley, P. Wright, and M. Montminy. 1998. Analysis of an activator: coactivator complex reveals an essential role for secondary structure in transcriptional activation. Mol. Cell 2:353-359[CrossRef][Medline]. |
| 36. |
Parker, D.,
M. Rivera,
T. Zor,
A. Henrion-Caude,
I. Radhakrishnan,
A. Kumar,
L. H. Shapiro,
P. E. Wright,
M. Montminy, and P. K. Brindle.
1999.
Role of secondary structure in discrimination between constitutive and inducible activators.
Mol. Cell. Biol.
19:5601-5607 |
| 37. |
Pugazhenthi, S.,
T. Boras,
D. O'Connor,
M. K. Meintzer,
K. A. Heidenreich, and J. E. Reusch.
1999.
Insulin-like growth factor I-mediated activation of the transcription factor cAMP response element-binding protein in PC12 cells. Involvement of p38 mitogen-activated protein kinase-mediated pathway.
J. Biol. Chem.
274:2829-2837 |
| 38. | Radhakrishnan, I., G. C. Perez-Alvarado, D. Parker, H. J. Dyson, M. Montminy, and P. E. Wright. 1997. Solution structure of the KIX domain of CBP bound to the transactivation domain of CREB: a model for activator-coactivator interactions. Cell 91:741-752[CrossRef][Medline]. |
| 39. |
Seternes, O. M.,
U. Moens, and B. Johansen.
1999.
A dominant role for the Raf-MEK pathway in forskolin, 12-O-tetradecanoyl-phorbol acetate, and platelet-derived growth factor-induced CREB (cAMP-responsive element-binding protein) activation, uncoupled from serine 133 phosphorylation in NIH 3T3 cells.
Mol. Endocrinol.
13:1071-1083 |
| 40. | Shaywitz, A. J., and M. E. Greenberg. 1999. CREB: a stimulus-induced transcription factor activated by a diverse array of extracellular signals. Annu. Rev. Biochem. 68:821-861[CrossRef][Medline]. |
| 41. | Songyang, Z., S. Blechner, N. Hoagland, M. F. Hoekstra, H. Piwnica-Worms, and L. C. Cantley. 1994. Use of an oriented peptide library to determine the optimal substrates of protein kinases. Curr. Biol. 4:973-982[CrossRef][Medline]. |
| 42. | Struthers, R. S., W. W. Vale, C. Arias, P. E. Sawchenko, and M. R. Montminy. 1991. Somatotroph hypoplasia and dwarfism in transgenic mice expressing a non-phosphorylatable CREB mutant. Nature 350:622-624[CrossRef][Medline]. |
| 43. | Walsh, D. A., and S. M. V. Patten. 1994. Multiple pathway signal transduction by the cAMP-dependent protein kinase. FASEB J. 8:1227-1236[Abstract]. |
| 44. |
Woloshin, P.,
K. Walton,
R. Rehfuss,
R. Goodman, and R. Cone.
1992.
3',5' cyclic adenosine monophosphate-regulated enhancer binding (CREB) activity is required for normal growth and differentiated phenotype in the FRTL5 thyroid follicular cell line.
Mol. Endocrinol.
6:1725-1733 |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»